Biopharmaceuticals market seen reaching $764.9 billion by 2035

Market Research Future says the global biopharmaceuticals market is projected to grow from $401.6 billion in 2025 to $764.9 billion by 2035, driven by chronic disease demand, oncology development and manufacturing expansion. North America leads revenue now, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - Biopharmaceuticals are moving deeper into mainstream care as chronic diseases, cancer and metabolic disorders expand the addressable market. - Faster manufacturing, broader regulation and payer pressure are reshaping how biologic drugs are developed, priced and delivered. - Market Research Future projects the sector to nearly double by 2035, reaching $764.9 billion from $401.6 billion in 2025.

What happened: - Market Research Future said the global biopharmaceuticals market will grow at a 6.6% CAGR from 2026 to 2035. - The market is expected to reach $430.2 billion in 2026. - The forecast points to two major policy drivers: the U.S. Inflation Reduction Act’s Medicare negotiation provisions and the EU Pharmaceutical Package revision. - Manufacturing is shifting from fixed stainless-steel facilities to single-use bioreactors, continuous perfusion and modular pod systems. - The company highlighted a free sample request and a customization request for its report on the market.

The details: - Lonza committed CHF 500 million to expand biologics capacity in Visp. - Samsung Biologics launched Plant 5 with 180,000 litres of capacity. - Continuous downstream processing is estimated to cut purified antibody costs by 30% to 40% versus legacy batch chromatography. - Global mammalian cell culture capacity has passed 8.1 million litres. - North America holds 40.5% of global revenue. - Asia-Pacific is the fastest-growing region, with an 8.9% CAGR through 2035. - The U.S. accounts for about 86.4% of North American revenue. - Canada contributes $14.6 billion to the regional market. - Mexico is the fastest-growing North American market at 7.9% CAGR. - Europe is the second-largest market at $104.4 billion in 2025. - China contributes $31.4 billion in Asia-Pacific revenue. - India is the fastest-growing Asia-Pacific market at 9.8% CAGR. - Brazil anchors South America with 58.7% of regional revenue. - Saudi Arabia contributes $4.1 billion in the Middle East and Africa region. - The top five companies control an estimated 34% to 38% of market revenue. - Roche, Johnson & Johnson, Merck & Co., AbbVie and Pfizer were listed among the leading participants. - Novo Nordisk committed $4.1 billion in June 2024 to a North Carolina fill-finish facility, with production ramping from 2027. - CMS published negotiated Medicare prices for the first ten selected drugs in August 2024, with reductions of 38% to 79% versus 2023 list prices, effective January 2026.

Between the lines: - The market’s growth is being pulled by both demand and supply. More patients need biologics, but manufacturers also need newer production methods to keep up. - Oncology remains the dominant application because high-priced therapies can scale quickly across multiple tumor types. - Metabolic disorders are the fastest-growing application because obesity and type 2 diabetes create a large, durable patient base. - Regulatory speed matters because earlier launches can materially lift lifetime product value. - Regional competition is widening. North America still leads, but policy support and manufacturing investment are helping Asia-Pacific grow faster.

What's next: - Market Research Future expects continued gains through 2035 as chronic disease prevalence rises and more biologics move through the pipeline. - AI-designed candidates, platform reuse and supply-chain regionalization are expected to shape the next phase of development. - Payers are likely to push more outcomes-based contracts, especially for one-time therapies priced above $1 million. - Emerging-market access could expand further as India and Brazil keep linking local manufacturing to public procurement.

The bottom line: - Biopharmaceuticals are becoming a larger, more industrialized global market, with growth increasingly tied to manufacturing scale, regulatory acceleration and demand from chronic disease and oncology.